CAS: 34368-04-2; 4-(2-((4-(4-Hydroxyphenyl)Butan-2-yl)Amino)Ethyl)Benzene-1,2-Diol

该化合物是一种合成催化素胺,是一种主要用于临床环境治疗心脏衰竭和心动冲击的强效非热带制剂,主要用于乙型-1肾上腺受体,导致心肌萎缩和心率上升,同时表现出某些乙型-2肾上腺活性活动,可导致血管畸变.多丁胺的化学配方为C18H23NO3,其分子重量约为301.39克/摩尔.一般是静脉注射,原因是其行动迅速和半衰期短.多丁胺的特点是能够提高心脏产出,而不会大幅增加系统的血管抗药性,因此在急性心脏衰竭情况下特别有用.化合物通常作为种族混合物供应,其中一种抗生素有助于其积极的异性反应效应.副作用可能包括心肌炎,心律不齐和低血压,因此在管理期间需要谨慎监测.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号61413-44-3 N-(3,4-dimethox... | CAS号120-20-7 3,4-二甲氧基苯乙胺 | CAS号3815-30-3 反-4-(4-甲氧苯基)-3-...

合成工艺路线路线简述

    📜N-(3,4-二甲氧基苯乙基)-4-(4-甲氧基苯基)丁-2-胺置于水,氢溴酸,溶剂黄146,盐酸体系中,用 水 用作溶剂,化学反应 9.0H,以89.8%的收率获得多巴酚丁胺
    参考文献:Wo2008/47382
    标题:Wo2008/47382

    海关参考信息

    专利信息


    专利号:US-9353057-B2
    优先权日:2003-12-30
    标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
    发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA
    权利人:XENOPORT INC
    摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-11766432-B2
    优先权日:2018-07-27
    标题 :Cleavable conjugates of catechol compounds and water-soluble polymers and methods of treatment using the same
    发明人:BENTLEY MICHAEL; FANG ZHIHAO; WEIMER REBECCA; VIEGAS TACEY; MOREADITH RANDALL
    权利人:SERINA THERAPEUTICS INC
    摘要:Described are conjugates comprising a water-soluble polymer linked to a compound comprising a catechol moiety via a cleavable linkage, wherein the cleavable linkage is formed between the water-soluble polymer and a first phenolic hydroxyl group of the catechol moiety and a second phenolic hydroxyl group of the catechol moiety is linked to a blocking group wherein the rate of hydrolytic release of the compound comprising the catechol moiety is controlled, at least in part, through structure or design of the blocking group on the second phenolic hydroxyl group of the catechol moiety. Therefore, the rate of hydrolytic release of the compound comprising the catechol moiety can be tuned through structural design of the group on the second phenolic hydroxyl group of the catechol moiety. Compounds used in the synthesis of the described conjugates and methods of using the described conjugate and other compounds in the treatment of dopamine-responsive disorders are also described.

    专利号:US-2008090885-A1
    优先权日:2006-10-12
    标题:Preparation of losartan 5-carboxylic acid and use thereof
    发明人:CHEN LIQIN; LI JIAN; SHEN YINGZHONG
    权利人:CHEN LIQIN; LI JIAN; SHEN YINGZHONG
    摘要:A method for synthesis of losartan 5-carboxylic acid (EXP-3174).

    专利号:US-8017776-B2
    优先权日:2003-07-15
    标题 :Methods for synthesis of acyloxyalkyl compounds
    发明人:BHAT LAXMINARAYAN; GALLOP MARK A
    权利人:XENOPORT INC
    摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.

    专利号:US-12295961-B2
    优先权日:2009-12-31
    标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
    发明人:DHINGRA OM
    权利人:MARIUS PHARMACEUTICALS INC
    摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Ruffolo RR Jr. The pharmacology of dobutamine. Am J Med Sci. 1987 Oct;294(4):244-8. doi: 10.1097/00000441-198710000-00005. 29(4):490-498. doi: 10.5935/0103-507X.20170068.
    3: Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002 Jul 20;360(9328):196-202. doi: 10.1016/s0140-6736(02)09455-2. 138(1 Pt 1):78-86. doi: 10.1016/s0002-8703(99)70250-4. 37(1):14-23. doi: 10.1007/s00246-015-1263-9. Epub 2015 Sep 7. Erratum in: Pediatr Cardiol. 2016 Dec 1;: 9(4):e95644. doi: 10.1371/journal.pone.0095644.
    7: Al Madfai F, Valah B, Zaidi STR, Wanandy T, Ming LC, Peterson GM, Patel RP. Stability of dobutamine in continuous ambulatory delivery devices. J Clin Pharm Ther. 2018 Aug;43(4):530-535. doi: 10.1111/jcpt.12674. Epub 2018 Mar 2. 20(2):134. doi: 10.14744/AnatolJCardiol.2018.50708.

    合成参考文献


    参考文献:10.1007/s10554-010-9598-z
    摘要:Innocenti F, Agresti C, Baroncini C, Caldi F, Mannucci E, Monami M, Pini R. Prognostic value of dobutamine stress echocardiography in diabetic patients. The International Journal of Cardiovascular Imaging. 2010 Feb 14;26(5):499–507. doi: 10.1007/s10554-010-9598-z.
    参考文献:10.1186/cc8875
    摘要:Mayer J, Boldt J, Mengistu AM, Röhm KD, Suttner S. Goal-directed intraoperative therapy based on autocalibrated arterial pressure waveform analysis reduces hospital stay in high-risk surgical patients: a randomized, controlled trial. Crit Care. 2010;14(1):R18.
    参考文献:10.1007/s00259-005-1965-y
    摘要:Schuijf JD, Poldermans D, Shaw LJ, Jukema JW, Lamb HJ, de Roos A, Wijns W, van der Wall EE, Bax JJ. Diagnostic and prognostic value of non-invasive imaging in known or suspected coronary artery disease. European Journal of Nuclear Medicine and Molecular Imaging. 2005 Nov 30;33(1):93–104. doi: 10.1007/s00259-005-1965-y.
    参考文献:10.1186/cc10306
    摘要:Konings MK, Grundeman PF, Goovaerts HG, Roosendaal MR, Hoefer IE, Doevendans PA, Rademakers FE, Buhre WF. In-vivo validation of a new non-invasive continuous ventricular stroke volume monitoring system in an animal model. Crit Care. 2011 Jul 11;15(4):R165.
    参考文献:10.1007/s10741-011-9265-z
    摘要:Carubelli V, Metra M, Lombardi C, Bettari L, Bugatti S, Lazzarini V, Dei Cas L. Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment. Heart Fail Rev. 2012 Mar;17(2):271–82. doi: 10.1007/s10741-011-9265-z.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知